AstraZeneca may be 'close to a breakthrough' on COVID-19 antibody treatment

Organisation: Position: Deadline Date: Location:

Scientists working on coronavirus treatments may be close to a breakthrough on an antibody treatment that could save the lives of people who become infected, The Guardian says it has been reported.

An injection of cloned antibodies that counteract COVID-19 could prove significant for those in the early stages of infection, according to the British-Swedish pharmaceutical company AstraZeneca.

The report quotes AstraZeneca’s CEO Pascal Soriot as saying that the treatment being developed is “a combination of two antibodies” in an injected dose “because by having both you reduce the chance of resistance developing to one antibody”.

Antibody therapy is more expensive than vaccine production, with Soriot saying the former would be prioritised for the elderly and vulnerable “who may not be able to develop a good response to a vaccine”.

The report says AstraZeneca has signed a deal with the Coalition for Epidemic Preparedness Innovations (Cepi) to help manufacture 300m globally accessible doses of the coronavirus vaccine candidate being developed by the Jenner Institute at the University of Oxford.

 

Full report in The Guardian

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.